Crossing the ADC inflection points: what separates clinical success from failure

“Drug development is not a race to be first; it is a race to win. History is full of examples where being first did not matter, but being right did.”

Lauren Coyle, Launch Commissioning Editor, Bioconjugate Insights, speaks with Antoine Yver, Board Chair, Ona Therapeutics, with more than three and a half decades of experience shaping global cancer drug development. In this conversation, they explore what determines whether an ADC successfully crosses the critical threshold and how teams should rethink dose finding, toxicity, and what it truly takes to set a program up for long-term success in the clinic.

Please enter your email to access content Read now